Anaplastic thyroid cancer (ATC) is a rapidly growing, lethal malignancy posing challenges for timely diagnosis and treatment, resulting in a median survival of 5 months. Currently, effective neoadjuvant therapy has not been established for ATC and other advanced thyroid cancers, although both targeted therapy and immunotherapy are being actively investigated for these cases. This case highlights the transformative impact of neoadjuvant therapy with tyrosine kinase inhibitors (TKI) on an ATC, suggesting of potential implications of this treatment approach.
No takes yet. Share an insight, caveat, or question.
Kuruppu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: